84 related articles for article (PubMed ID: 16334135)
1. Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study.
Maisano R; Caristi N; Mare M; Mafodda A; Carboni R; Montalto E; Iorfida M; Nardi M
Anticancer Res; 2005; 25(6C):4513-7. PubMed ID: 16334135
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study.
Maisano R; Caristi N; Mare M; Raffaele M; Iorfida M; Mafodda A; Zavettieri M; Nardi M
Anticancer Res; 2007; 27(4C):2871-5. PubMed ID: 17695463
[TBL] [Abstract][Full Text] [Related]
3. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Rocca A; Maltoni R; Passardi A; Massa I; Aquilina M; Ridolfi R; Ibrahim T; Cecconetto L; Sarti S; Pietri E; Nanni O; Amadori D
Cancer Chemother Pharmacol; 2010 Apr; 65(5):871-6. PubMed ID: 19693503
[TBL] [Abstract][Full Text] [Related]
4. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S;
Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Nolè F; Catania C; Munzone E; Rocca A; Verri E; Sanna G; Ascione G; Adamoli L; Zampino MG; Minchella I; Goldhirsch A
Clin Breast Cancer; 2006 Feb; 6(6):518-24. PubMed ID: 16595035
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.
Susnjar S; Bosnjak S; Radulovic S; Stevanovic J; Gajic-Dobrosavljevic M; Kreacic M
J BUON; 2007; 12(2):189-96. PubMed ID: 17600871
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Massacesi C; La Cesa A; Marcucci F; Pilone A; Rocchi MB; Zepponi L; Santini D; Tonini G; Burattini L
Oncology; 2006; 70(4):294-300. PubMed ID: 17047400
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
[TBL] [Abstract][Full Text] [Related]
17. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Estévez LG; Batista N; Sánchez-Rovira P; Velasco A; Provencio M; León A; Dómine M; Cruz J; Rodríguez M
Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
[TBL] [Abstract][Full Text] [Related]
20. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
